Skip to main content Skip to section navigation Skip to footer
  • Medical Professionals
    • Information for Healthcare Providers
    • Clinical Studies
    • Expanded Access
    • Educational Grants
    • Request Information
  • Press Releases
  • Suppliers

Atara Biotherapeutics

  • Our Company
    • About Us
    • Responsibility
  • Technology
    • Technology
    • Manufacturing
    • CAR T
  • Pipeline
    • Atara Pipeline
    • Tab-cel®
    • ATA3219
    • ATA3431
  • Patients & Families
    • Our Mission
    • ATA3219 Trial (NHL)
    • ATA3219 Trial (SLE/LN)
    • Stories of Strength
    • About EBV
    • PTLD
    • Clinical Studies
    • Expanded Access
  • Investors & Media
    • Investors & Media
    • News & Events
    • Financial Results
    • ATRA Stock
    • Analyst Coverage
    • SEC Filings
    • Governance
  • Careers
    • Careers Home
    • Career Areas
    • Job Search
  • Contact
  • Medical Professionals
  • Press Releases
  • Suppliers
  • LinkedIn
  • Twitter
  • News
  • Careers
Investors & Media

Investors & Media

  • Investors & Media
  • News & Events
    • Overview
    • Press Releases
    • Events
    • Presentations
    • Email Alerts
    • Investor & Media Contacts
  • Financial Results
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • ATRA Stock
    • Overview
    • Charts
    • Historical Data
    • FAQ
    • Classification Info
  • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Contact the Board

Investor Relations

News & Events

Press Releases

  • News & Events

  • Overview
  • Press Releases
  • Events
  • Presentations
  • Email Alerts
  • Investor & Media Contacts
Mar 28, 2024 8:30 am EDT

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Feb 29, 2024 9:05 am EST

Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy

Feb 28, 2024 4:30 pm EST

Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference

Feb 14, 2024 9:00 am EST

Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Jan 31, 2024 6:30 pm EST

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Jan 08, 2024 9:00 am EST

Atara Biotherapeutics Announces $15 Million Registered Direct Offering

Jan 08, 2024 8:00 am EST

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 04, 2024 4:01 pm EST

Atara Biotherapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023 4:01 pm EST

Atara Biotherapeutics Announces Closing of Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories

Dec 11, 2023 12:00 pm EST

Atara Biotherapeutics Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

  • Previous Pagearrow_back
  • Page 1…
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 37
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Atara Biotherapeutics
  • Home
  • Site Map
  • Terms of Use
  • Privacy Policy
  • Medical Professionals
  • Press Releases
  • Suppliers
LinkedIn Icon Twitter Icon
  • Our Company
  • Technology
  • Pipeline
  • Investors and Media
  • Patients and Families
  • Careers
  • Contact
  • Our Company
  • About Us
  • Responsibility
  • Technology
  • Technology
  • Manufacturing
  • CAR T
  • Investors and Media
  • Investors & Media
  • News & Events
  • Financial Results
  • ATRA Stock
  • Analyst Coverage
  • SEC Filings
  • Governance
  • Pipeline
  • Atara Pipeline
  • Tab-cel®
  • ATA3219
  • ATA3431
  • Careers
  • Careers Home
  • Career Areas
  • Job Search
  • Contact
  • Patients and Families
  • Our Mission
  • Stories of Strength
  • About EBV
  • PTLD
  • Clinical Studies
  • Expanded Access

© 2025 Atara Biotherapeutics, Inc. All rights reserved. Notice of Data Breach